Home / 2021 / February / 19

Daily Archives: February 19, 2021

Sumo Logic Announces Upcoming Conference Participation

REDWOOD CITY, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) — Sumo Logic, (Nasdaq: SUMO) the pioneer in continuous intelligence, announced today that members of its management team will present at the following investor conferences:

  • The Morgan Stanley Technology, Media and Telecom Conference, March 2nd at 2:00PM Pacific Time, 5:00 PM Eastern Time
  • The Berenberg Cyber Security & DevOps Conference, March 12th at 11:00AM Pacific Time, 2:00 PM Eastern Time

Links to the webcasts of these events will be available on the investor relations section of the Company’s website at http://investor.sumologic.com.

Additional Resources

  • Sign up for a free trial of Sumo Logic

About Sumo Logic
Sumo Logic Inc., (Nasdaq: SUMO), is the pioneer in continuous intelligence, a new category of software, which enables organizations of all sizes to address the data challenges and opportunities presented by digital transformation, modern applications, and cloud computing. The Sumo Logic Continuous Intelligence Platform™ automates the collection, ingestion, and analysis of application, infrastructure, security, and IoT data to derive actionable insights within seconds. More than 2,100 customers around the world rely on Sumo Logic to build, run, and secure their modern applications and cloud infrastructures. Only Sumo Logic delivers its platform as a true, multi-tenant SaaS architecture, across multiple use-cases, enabling businesses to thrive in the Intelligence Economy. For more information, visit www.sumologic.com.

Sumo Logic is a trademark or registered trademark of Sumo Logic in the United States and in foreign countries. All other company and product names may be trademarks or registered trademarks of their respective owners.

Any information regarding offerings, updates, functionality, or other modifications, including release dates, is subject to change without notice. The development, release, and timing of any offering, update, functionality, or modification described herein remains at the sole discretion of Sumo Logic, and should not be relied upon in making a purchase decision, nor as a representation, warranty, or commitment to deliver specific offerings, updates, functionalities, or modifications in the future.

Investor Relations Contact:
Paul Thomas
Sumo Logic
pthomas@sumologic.com
(650) 214-3847

Media Contacts:
Melissa Liton
Sumo Logic
mliton@sumologic.com
(650) 814-3882

FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS)

First international council to support accelerated drug development for Angelman syndrome and related neurodevelopmental disorders

DOWNERS GROVE, Ill., Feb. 19, 2021 (GLOBE NEWSWIRE) — FAST (Foundation for Angelman Syndrome Therapeutics) and the Simons Foundation Autism Research Initiative (SFARI) today announced a collaboration to launch the International Angelman Syndrome Research Council (INSYNC-AS). Using a robust integrated approach, the Council will evaluate and drive research initiatives in Angelman syndrome (AS) and other neurodevelopmental disorders (NDDs).

INSYNC-AS’s goal is to build community and leverage the combined skills of world leaders in neuroscience, clinical research, genetics, drug development, regulatory expertise, and other thought leaders, in order to accelerate drug development for Angelman syndrome and other related disorders. The Council was formed to be an innovative model that encourages research in areas where gaps need to be filled. A multi-functional combination of skill sets and expertise will help to advance FAST’s deep funding strategies, while leveraging these learnings to other NDDs.

“The emergence of novel therapeutic platforms such as gene therapy and genome editing has created exciting opportunities for possible treatments for neurodevelopmental disorders. INSYNC-AS will be a great way to help the Angelman syndrome community assess, and potentially direct, these technologies to therapies,” said James Wilson, MD, PhD, a professor and director of the Penn Gene Therapy Program and Penn Orphan Disease Center, a member of the Council.

This Council will take the cutting-edge scientific discoveries available in Angelman syndrome research to the next level by promoting and growing the work being pursued by our current thought leaders, while advancing strategies that are not yet being implemented. By sharing knowledge and clinical expertise, the Angelman syndrome community can be sure that for AS, and other similar NDDs, world leaders are working to the highest quality through state-of-the-art initiatives.

Dr. John Spiro, interim director of SFARI, stated, “SFARI is excited about partnering with Dr. Allyson Berent, and the entire Angelman syndrome community, to capitalize on what they have learned from their successes in bringing potential therapeutics to individuals with AS. SFARI hopes to keep the momentum going to make those treatments even more effective and durable, and to extend the lessons learned to other neurodevelopmental disorders with known genetic causes. FAST’s sense of urgency and laser focus on moving findings from the lab into clinical trials is an inspiration to all of us who work in this field.”

“The inspiration to establish the INSYNC-AS Consortium was to further all translational research avenues for Angelman syndrome, leaving no stone unturned, highlighting FAST’s mission in every way,” stated Dr. Allyson Berent, FAST’s Chief Science Officer.   “This is beyond exciting for all of those living with Angelman syndrome, and hundreds of other neurodevelopmental disorders. This collaboration between FAST and SFARI is just spectacular for our entire AS community and hundreds of other neurodevelopmental disorders.”

About FAST

FAST (Foundation for Angelman Syndrome Therapeutics) is a Section 501(c)(3) nonprofit research organization singularly focused on funding research that holds the greatest promise of treating Angelman syndrome. FAST is the largest, nongovernmental funder of Angelman-specific research. Paula Evans, mother of a girl with Angelman syndrome, founded FAST in 2008. In 2017, FAST formed GeneTx Biotherapeutics to develop GTX-102, and antisense oligonucleotide, for human clinical trials. More information can be found at www.CureAngelman.org.

About Angelman Syndrome

Angelman syndrome is a rare, neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. It is estimated to affect 1 in 12,000 to 1 in 20,000 people globally. Individuals with Angelman syndrome have developmental delays, balance issues, motor impairment, and debilitating seizures. Some are unable to walk and most do not speak. While individuals with Angelman syndrome have a normal lifespan, they require continuous care and are unable to live independently. There are currently no approved therapies for Angelman syndrome; however, several symptoms of this disorder can be reversed in adult animal models of Angelman syndrome, suggesting that improvement of symptoms can potentially be achieved at any age.

About SFARI

SFARI’s mission is to improve the understanding, diagnosis and treatment of autism spectrum disorders by funding innovative research of the highest quality and relevance. Since its launch in 2006, SFARI has supported over 550 investigators doing autism-related research in the U.S. and abroad. Research projects include studies at the genetic, molecular, cellular, circuit and behavioral levels, in addition to clinical and translational studies.

Allyson Berent, DVM, DACVIM
allyson.berent@cureangelman.org

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

  • Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries
  • Memorandum of understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility

GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance (Gavi), to provide 1.1 billion cumulative doses of NVX-CoV2373, Novavax’ recombinant protein-based COVID-19 vaccine candidate, for the COVAX Facility. The vaccine doses will be manufactured and distributed globally by Novavax and Serum Institute of India (SII), the latter under an existing agreement between Gavi and SII. NVX-CoV2373 is being studied in two ongoing pivotal Phase 3 clinical trials: in the United States and Mexico, as well as in the United Kingdom (U.K.), for the prevention of COVID-19. Novavax has previously reported positive interim efficacy results from its U.K. trial.

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, and the World Health Organization (WHO), who are working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, civil society organisations and others to guarantee fair and equitable access to the vaccine for every country in the world. COVAX currently includes more than 190 participating economies.

“We are proud to partner with all the COVAX collaborators and Serum Institute of India to provide global public health leadership and ensure that all countries have broad access to NVX-CoV2373,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Novavax will play a critical role in the worldwide effort to provide access to safe and effective vaccines to end the pandemic.”

Gavi leads the design and implementation of the COVAX Facility and will work with Novavax to finalize an advance purchase agreement (APA) for vaccine supply and global distribution allocation via the COVAX Facility and its partners.

“This agreement brings the COVAX Facility one step closer to its goal of supplying vaccines globally and ending the acute phase of the pandemic,” said Dr. Seth Berkley, CEO of Gavi. “It helps us close in on our goal of delivering two billion doses in 2021 and increases the range of vaccines available to us as we build a portfolio suitable for all settings and contexts.”

CEPI has provided critical support to Novavax, including the commitment of approximately $400 million to advance early clinical development and manufacturing scale-up in multiple facilities around the globe. Novavax has created a global supply network to ensure there can be adequate and equitable supply of NVX-CoV2373 across the globe. Consistent with its mission to increase global manufacturing capacity and ensure broad, equitable supply distribution, Novavax licensed its NVX-CoV2373 technology to SII with no upfront, milestone or technology transfer payments. With this strategic partnership in place, Novavax and SII are jointly committed to deliver 1.1 billion doses to the COVAX Facility. For supply of NVX-CoV2373 to COVAX, Novavax is expected to supply doses primarily to high-income countries (HICs), with SII providing the majority of supply for low-, middle, and upper-middle-income countries, (LMICs, UMICs), utilizing a tiered pricing schedule.

“With this MOU in place, the vaccine candidate developed by our partners at Novavax is poised to play a significant role in combatting COVID-19 around the world,” said Dr. Richard Hatchett, CEO of CEPI. “CEPI’s investments in this vaccine have been pivotal to enabling equitable access to a significant volume of this vaccine through COVAX.”

“We are pleased to deepen our partnership with Novavax and COVAX to increase the doses of vaccine available to benefit humanity,” said Adar Poonawalla, Chief Executive Officer, Serum Institute of India.” This global collaboration is vital to ensure that the largest possible amount of vaccine is available to reach individuals across the broadest segment of countries.

NVX-CoV2373 was the first vaccine to demonstrate clinical efficacy against the original strain of COVID-19 and both of the rapidly emerging variants in the United Kingdom and South Africa. NVX-CoV2373 can neither cause COVID-19 nor can it replicate. It is shipped in a ready-to-use liquid formulation. Because it is stable at 2°C to 8°C (refrigerated), existing vaccine supply chain channels can be used for its distribution.

About NVX-CoV2373

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax’ patented saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response numerically superior to that seen in human convalescent sera in Phase 1/2 clinical testing. NVX-CoV2373 is currently being evaluated in two pivotal Phase 3 trials: a trial in the U.K that demonstrated 89.3 percent overall efficacy and 95.6 percent against the original strain in a post-hoc analysis, and the PREVENT-19 trial in the U.S. and Mexico that began in December. It is also being tested in two ongoing Phase 2 studies that began in August: A Phase 2b trial in South Africa that demonstrated up to 60 percent efficacy against newly emerging escape variants, and a Phase 1/2 continuation in the U.S. and Australia.

About Matrix-M™

Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Novavax Forward Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:         

Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Jennifer Porcelli | 617-974-8659
jporcelli@soleburytrout.com

Media
Laura Keenan | 410-419-5755
Amy Speak | 617-420-2461
media@novavax.com

Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma

–the 3rd sNDA for Toripalimab in China

SHANGHAI, China, Feb. 19, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for Toripalimab combined with chemotherapy for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.

The supplemental NDA is based on the JUPITER-02 study (NCT03581786), which is a randomized, double-blind, placebo-controlled Phase III study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. The results of the study showed that Toripalimab combined with gemcitabine/cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma significantly prolonged the progression-free survival as compared with the standard first-line treatment of gemcitabine/cisplatin. This study is the world’s largest international Phase III clinical study for any checkpoint inhibitor combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Junshi Biosciences has developed clinical programs using Toripalimab alone or in combination with other therapies for the treatment of nasopharyngeal carcinoma regardless of extent of prior treatments. The company has submitted two sNDAs of toripalimab for the treatment of NPC in China. Toripalimab also obtained Breakthrough Therapy and Orphan Drug Designations from the US FDA for this indication, and its Biologics License Applications (BLA) in the United States will be submitted in the near future. Toripalimab is likely to become the first Chinese anti-PD-1 monoclonal antibody to achieve commercialization in the overseas markets.

About Nasopharyngeal carcinoma
Nasopharyngeal carcinoma is a malignant tumor that occurs in nasopharyngeal mucosal epithelium, which is one of the most common head and neck cancers. According to the World Health Organization, the number of newly diagnosed nasopharyngeal carcinoma cases in 2020 has reached approximately 133,000 worldwide, and nearly half of the cases occurred in China.

About Toripalimab
Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. More than thirty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. On 17 December 2018, Toripalimab obtained a conditional approval from the NMPA for the second-line treatment of unresectable or metastatic melanoma. Toripalimab was included in the 2019 and 2020 Guidelines of Chinese Society of Clinical Oncology (CSCO) for the Diagnosis and Treatment of Melanoma. Two supplemental New Drug Applications (“NDAs”) of Toripalimab for the third-line treatment of recurrent or metastatic nasopharyngeal carcinoma and the second-line treatment of metastatic urothelial carcinoma were accepted by the NMPA in April 2020 and May 2020, respectively. Both supplemental NDAs received priority review designations from the NMPA in July 2020. In addition, Toripalimab has been granted Breakthrough Therapy Designation (“BTD”) by the US Food and Drug Administration (“FDA”) for the treatment of recurrent or metastatic nasopharyngeal carcinoma in September 2020. In December 2020, Toripalimab Injection was successfully included in the updated National Reimbursement Drug List (“NRDL”). Currently, Toripalimab has been granted 1 Breakthrough, 1 Fast Track , and 3 Orphan Drug Designations by the FDA for the treatment of mucosal melanoma, nasopharyngeal carcinoma, and soft tissue sarcoma.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 27 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016, China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2, which has entered clinical trials and is now a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team
Junshi Biosciences
info@junshipharma.com
+86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+86 021-6105 8800

Sophi.io ได้รับการยกย่องว่าเป็นพันธมิตรด้านเทคโนโลยีที่โดดเด่นของ WordPress VIP

โตรอนโต, Feb. 19, 2021 (GLOBE NEWSWIRE) — WordPress VIP ผู้ให้บริการชั้นนำของ WordPress ระดับองค์กร ได้เพิ่ม Sophi.io ซึ่งเป็นระบบปัญญาประดิษฐ์โดย The Globe and Mail ในโปรแกรม Technology Partnership อันทรงเกียรติ Sophi เข้าร่วมกลุ่มบริษัทเทคโนโลยีระดับองค์กรขนาดเล็กที่ให้บริการลูกค้า VIP และเป็นพันธมิตรรายแรกที่ให้บริการจัดการเนื้อหาอัตโนมัติที่ขับเคลื่อนด้วย AI นอกเหนือจากโซลูชันวิเคราะห์เชิงคาดการณ์และ Paywall

“เรารู้สึกยินดีเป็นอย่างยิ่งที่ได้ต้อนรับ Sophi เข้าสู่ระบบนิเวศของการผสานรวมองค์กรที่กำลังเติบโตซึ่งมีให้บริการสำหรับลูกค้า WordPress VIP” Nick Gernert, CEO ของ WordPress VIP กล่าว “เนื้อหาคือหัวใจของการเติบโตขององค์กร และพันธมิตรของเราคือผู้ที่มีบทบาทสำคัญที่จะช่วยให้ผู้เผยแพร่และนักการตลาดสามารถสร้างประสบการณ์ที่มีความหมายกับลูกค้าด้วยเครื่องมือการเล่าเรื่องที่มีประสิทธิภาพ”

WordPress VIP ให้บริการแพลตฟอร์มระบบคลาวด์ WordPress ที่มีการจัดการเต็มรูปแบบสำหรับขนาด ความปลอดภัย ประสิทธิภาพ และความยืดหยุ่น รวมถึงคำแนะนำแบบครบวงจรและการสนับสนุนแบบลงมือปฏิบัติ โดยมีลูกค้าองค์กรบางส่วน ได้แก่ Capgemini, Facebook, Microsoft และ News Corp เป็นต้น

Greg Doufas, CTO ที่ The Globe and Mail ได้กล่าวว่า “เรารู้สึกตื่นเต้นที่นำ Sophi มาสู่ผู้ใช้ WordPress VIP ทุกคน Sophi นั้นถูกพัฒนาขึ้นมาสำหรับผู้เผยแพร่เนื้อหา ความร่วมมือครั้งนี้จะช่วยให้ Sophi สามารถเปลี่ยนแปลงวิธีการดำเนินธุรกิจของผู้เผยแพร่เนื้อหา และวิธีการที่ผู้อ่านได้รับบริการเนื้อหาอันมีค่า วิธีและสถานที่ที่พวกเขารับได้ไวที่สุด เราหวังว่าจะมีความสัมพันธ์ที่ดีกับ WordPress VIP”

ชุดโซลูชัน Sophi ที่ได้รับรางวัลนั้นถูกพัฒนาขึ้นโดย The Globe and Mail เพื่อช่วยให้ผู้เผยแพร่เนื้อหาตัดสินใจเชิงกลยุทธ์และยุทธวิธีที่สำคัญที่จะเปลี่ยนโฉมธุรกิจของตน มันเป็นชุดเครื่องมือที่ขับเคลื่อนด้วย ML และ NLP ซึ่งรวมถึง Sophi Automation สำหรับการดูแลเนื้อหา, Sophi for Paywalls และ Sophi Analytics ซึ่งเป็นระบบสนับสนุนการตัดสินใจสำหรับผู้เผยแพร่

เกณฑ์สำคัญสำหรับพันธมิตรด้านเทคโนโลยี ได้แก่ ความเชี่ยวชาญด้านผลิตภัณฑ์ที่ชัดเจนและกลยุทธ์การออกสู่ตลาดที่สร้างสรรค์ VIP จะตรวจสอบพันธมิตรทุกรายเพื่อหาบริษัทที่มีประวัติที่พิสูจน์แล้วว่าประสบความสำเร็จและมีการใช้งาน WordPress ขนาดใหญ่อย่างมีวิสัยทัศน์

สำหรับข้อมูลเพิ่มเติมเกี่ยวกับความร่วมมือของ Sophi กับ WordPress VIP โปรดไปที่ https://wpvip.com/partner/sophi

เกี่ยวกับ Sophi.io

Sophi.io (https://www.sophi.io) ถูกพัฒนาขึ้นโดย The Globe and Mail เพื่อช่วยผู้เผยแพร่เนื้อหาในการตัดสินใจเชิงกลยุทธ์และยุทธวิธีที่สำคัญ ซึ่งเป็นชุดเครื่องมือที่ขับเคลื่อนด้วย AI ซึ่งประกอบด้วย Sophi Automation และ Sophi for Paywalls รวมถึง Sophi Analytics ซึ่งเป็นระบบสนับสนุนการตัดสินใจสำหรับผู้เผยแพร่เนื้อหา Sophi ถูกออกแบบมาเพื่อปรับปรุงเมตริกที่มีความสำคัญต่อธุรกิจของคุณมากที่สุด เช่น การรักษาผู้สมัครสมาชิกและการเข้าซื้อกิจการ การมีส่วนร่วม ความใหม่ ความถี่และปริมาณ Sophi ยังขับเคลื่อนการจัดรูปแบบหนังสือพิมพ์และ ePapers แบบอัตโนมัติ

เกี่ยวกับ WordPress VIP

WordPress VIP เป็นผู้ให้บริการชั้นนำของ WordPress ระดับองค์กร แพลตฟอร์ม VIP ให้บริการการตลาดดิจิทัลระดับองค์กรและแพลตฟอร์มการเผยแพร่โดยมี WordPress เป็นหัวใจหลัก VIP รองรับแพลตฟอร์มการตลาดดิจิทัลระดับเรือธงสำหรับหลากหลายแบรนด์ที่มีชื่อเสียง เช่น Capgemini, Hachette Book Group และ Facebook ลูกค้าสำนักพิมพ์ดิจิทัลของเราครอบคลุมทั่ววงการสื่อ ตั้งแต่ร้านค้าเฉพาะแบรนด์ เช่น Quartz, TechCrunch และ FiveThirtyEight ไปจนถึงผู้เผยแพร่และเว็บไซต์ที่ใหญ่ที่สุดในโลกเช่น News Corp, Rolling Stone และ Abril

ด้วยพลัง ความยืดหยุ่น และความสามารถในการทำงานร่วมกันที่เหนือชั้น ทำให้ WordPress เป็นโซลูชันประสบการณ์ดิจิทัลขนาดใหญ่ที่ดีที่สุด เมื่อรวมกับการสนับสนุนจากผู้เชี่ยวชาญของ VIP ซึ่งเป็นโครงสร้างพื้นฐานที่ดีที่สุดในระดับเดียวกัน และเครือข่ายพันธมิตรที่ยอดเยี่ยม จึงเป็นการผสมผสานที่เหนือชั้น

ติดต่อด้านสื่อ

Jamie Rubenovitch
หัวหน้าฝ่ายการตลาด, Sophi.io,
The Globe and Mail
jrubenovitch@globeandmail.com

Face-to-face school session to start on March 1

The face-to-face school session which was postponed earlier following the spread of COVID-19, will be commencing on March 1.

Senior Education Minister Senator Datuk Dr Radzi Jidin said it involved pre-school, Year 1 and 2 classes while Year 3 to Year 6 sessions would start on March 8.

“Secondary school students in Group A states will start school on April 4 while secondary school students in Group B states will attend school on April 5 which is after the Sijil Pelajaran Malaysia (SPM) 2020 examination,” he told a media conference here today.

He said the decision to allow primary school pupils to start school session earlier was to allow pupils and teachers adapt to the new normal as well as the COVID-19 standard operating procedures.

Group A involves schools in Kedah, Johor, Kelantan and Terengganu while Group B involves schools in Perlis, Penang, Perak, Selangor, Negeri Sembilan, Melaka, Pahang, Sabah, Sarawak, Federal Territories of Kuala Lumpur, Labuan and Putrajaya.

He said the school calendar would remain as issued earlier.

“The opening dates are adopted by all government schools, government aided schools, private schools and institutes registered with the Education Ministry (MOE).

“Schools not registered with MOE are urged to follow the school opening dates and comply with all stipulated SOPs,” he said.

He said vocational colleges would open on March 1 while international schools and private educational institutions, including tuition centres, would open on March 8.

Radzi meanwhile said that MOE had planned carefully and the approach was taken based on input and feedback from all parties.

Meanwhile, when asked on streamlining DidikTV when school session begins, Radzi said the content of programmes for school students would be expanded considering primary school pupils would be starting school earlier.

On Wednesday, (Feb 17) , Prime Minister Tan Sri Muhyiddin Yassin launched DidikTV via channel 107 on MYTV, channel 147 on ASTRO and on ntv7 channel on UNIFI TV starting from 7 am to 12 midnight nationwide.

For parents who are worried about the COVID-19 numbers, he said it was the responsibility of MOE to provide access to education safely and at the same time did not want students to be left far behind in learning.

“If there is a problem of health, parents can inform the school. I am also seeking the cooperation of parents waiting for their children after school to comply with SOP outside the school compound such as physical distancing and so on,” Radzi said.

Commenting on the SPM 2020 examination which will start this Monday, he said the method of SPM implementation this year is very detailed so that students are safe with strict SOP when sitting for the examination.

“Usually, there is only one examination hall but this time we are providing alternative rooms if it is required by candidates.

“Apart from that, we also provide special rooms if students show symptoms of COVID-19 while isolation room and transit room are for the use of students,” he said.

SPM 2020 is scheduled to start on Monday and will end on March 25.

Source: BERNAMA News Agency

Hadi Awang discharged from IJN

PAS President Datuk Seri Abdul Hadi Awang was discharged from the National Heart Institute (IJN) today after being admitted there last Monday (Feb 15).

In a Facebook posting, Abdul Hadi expressed his gratitude to the doctors and staff at the Putrajaya Hospital Emergency Unit and IJN for their efficiency and high professionalism, and to all who have prayed for his health.

“During the treatment period, I have been following the local and international development especially on the National COVID-19 Immunisation Programme and the National Unity Policy which were launched by Prime Minister Tan Sri Muhyiddin Yassin, besides other measures to prevent COVID-19 and revive the country’s economy.

“Hopefully, everything can be achieved with the support from all,” he wrote.

It was reported that the Marang Member of Parliament was admitted to the Putrajaya Hospital for shortness of breath before he was transferred to IJN for further treatment on Monday.

Source: BERNAMA News Agency